A vaccine against the biggest bacterial killer on the planet is a step closer to being available with funding secured for preclinical trials.
Professor James Paton, Director of the University of Adelaide’s Research Centre for Infectious Diseases and his team have been working on a vaccine for Streptococcus pneumoniae (the pneumococcus) that could save two million lives globally a year and address the overuse of antibiotics that leads to resistance.
“The pneumococcus is the biggest bacterial killer on the planet. It’s the most common cause of pneumonia, which is responsible for about 20 per cent of deaths from all causes in children under 5 years in developing countries. Globally, the pneumococcus accounts for about two million deaths a year,” says Professor Paton.
Streptococcus pneumoniae, which is principally spread through close contact with infected but asymptomatic carriers, is the leading cause of sinus and ear infections, meningitis, sepsis and pneumonia. Ear infections are one of the most common childhood illnesses that are habitually treated with antibiotics, contributing to increasing bacterial resistance.
“Vaccinating people against Streptococcus pneumoniae would help to ameliorate the global challenge of increasing bacterial resistance to antibiotics,” says Professor Paton.
“The problem with the existing pneumococcal vaccine is that it targets the outside coat of complex carbohydrates – of which there are 98 structurally distinct types. The current vaccine costs about $150 a dose and only covers 13 types.
“What we have done is to remove this coat to expose all the surface proteins that are common to all pneumococcal types. The body mounts an immune response to these surface proteins if previously exposed or vaccinated.”
Sixteen months ago, Adelaide-based GPN Vaccines Pty Ltd was created to develop this novel “whole bacterial” vaccine (Gamma-PNTM) against Streptococcus pneumoniae. The company has already secured investment from local angel investors as well as a major grant from the National Health & Medical Research Council and a Commercialisation grant from the South Australian Government.
GPN Vaccines has now raised a further AUS$1.1 million from international and Australian-based investors that will be used for preclinical evaluation of the Gamma-PNTM vaccine. Toxicity tests will be carried out as well as the scale-up clinical grade manufacture of the vaccine in readiness for testing in a first-in-human clinical trial.
Learn more: STEP FORWARD FOR PNEUMONIA VACCINE DEVELOPMENT
The Latest on: Pneumonia
via Google News
The Latest on: Pneumonia
- Oral health crucial for preventing nonventilator hospital-acquired pneumonia, study sayson August 7, 2022 at 7:15 am
USA: A recent study published in Infection Control & Hospital Epidemiology supports the emerging body of evidence on the cruciality of oral health for the prevention of nonventilator hospital-acquired ...
- Pneumonia Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Updateon August 5, 2022 at 6:38 am
Summary clinical trial report, “Pneumonia Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update" provides an overview of ...
- Fred Astaire: 'He died in my arms' Star's final moments before dying of pneumoniaon August 5, 2022 at 4:00 am
THE DEATH of Fred Astaire back in 1987 was felt around the world as the star had become famous for his tap dancing and uncanny sense of rhythm. Having starred in more than 10 Broadway and West End ...
- Unibee Lung Support does not treat pneumonia in just 7 dayson August 4, 2022 at 4:00 am
The American Lung Association warns the public against trusting products that promise quick treatments for pneumonia, which usually takes weeks or even months to properly treat ...
- Inhaled nitric oxide may ease severe COVID-19 pneumonia in pregnant womenon August 3, 2022 at 11:00 am
High-dose inhaled nitric oxide (iNO200) is associated with a reduced need for oxygen supplementation and shorter hospital stay among pregnant patients with severe bilateral COVID-19 pneumonia, ...
- WATCH: Experts champion pneumonia vaccination in ‘JAB Well Done!’ webinaron August 2, 2022 at 2:45 am
Vaccination is one of the most vital and cost-effective tools available in health care to help prevent infectious diseases like pneumonia. MSD in the Philippines, together with the Pharmaceutical and ...
- Are You at Increased Risk of Getting Pneumococcal Pneumonia?on August 1, 2022 at 10:00 pm
To help reduce the burden of this lung disease, the American Lung Association and Pfizer are partnering to share important facts about pneumococcal pneumonia for adults 65 or older and adults 19-64 ...
- Nutrition, Pneumonia Severity May Predict Life Expectancy From Aspiration Pneumoniaon July 31, 2022 at 5:35 am
Poor nutritional status and increased severity of pneumonia were associated with higher mortality rates among patients with aspiration pneumonia, according to a recent study.
- The Latest on Community-Acquired Pneumonia in Kids: Diagnosis and Treatmenton July 26, 2022 at 12:19 pm
Dr William Basco reports on the 2022 Pediatric Academic Societies session on community-acquired pneumonia in children.
- Lack of proper oral hygiene can cause pneumonia while in the hospitalon July 26, 2022 at 11:04 am
Research shows a recent spike in non-ventilator hospital-acquired pneumonia cases, known as NV-HAP, is linked to poor oral hygiene.
via Bing News